Related Experiment Videos
The c-erbB3/HER3 receptor in human cancer
1ICRF Oncology Unit, Hammersmith Hospital, London.
Cancer Surveys
|January 1, 1996
Summary
c-erbB3, a receptor tyrosine kinase, heterodimerizes with other kinases to stimulate unique cellular responses. Its frequent overexpression in solid tumors makes it a promising target for novel cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- c-erbB3 (ErbB3) is a type I receptor tyrosine kinase.
- It functions as a receptor for NDF/heregulin.
- ErbB3 heterodimerizes with other receptor tyrosine kinases.
Purpose of the Study:
- To investigate the role of c-erbB3 in cellular signaling pathways.
- To explore the therapeutic potential of targeting c-erbB3 in cancer.
Main Methods:
- Analysis of c-erbB3 expression in tumor samples.
- Studies on heterodimerization of c-erbB3 with other receptor tyrosine kinases.
- Investigation of downstream signaling events mediated by c-erbB3 heterodimers.
Main Results:
- c-erbB3 exhibits limited intrinsic kinase activity.
- Heterodimerization with other kinases enables c-erbB3 to elicit distinct cellular responses.
- c-erbB3 is frequently overexpressed in common solid tumors.
Conclusions:
- c-erbB3 plays a significant role in cancer cell signaling through heterodimerization.
- The overexpression of c-erbB3 in tumors highlights its potential as a therapeutic target.
- Targeting c-erbB3 may offer a novel strategy for cancer treatment.